Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab


Tonyali O., Coskun U., Yuksel S., İNANÇ M., Bal O., Akman T., ...Daha Fazla

BREAST, cilt.25, ss.22-26, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Purpose: The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.